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ABSTRACT
Tumor necrosis factor a (TNFa), a potent inflammatory cytokine, has long been
established as a major driving force for pathologic inflammation. Currently, anti-TNFa
therapies are the standard in Inflammatory Bowel Disease (IBD) management; however,
one-third of IBD patients fail to respond to anti-TNFa therapies. Previous data from this
lab indicate that TNFa Converting Enzyme (TACE) inhibition does not ameliorate colitis
in BALB/C mice. Thus, we hypothesized that TNFa is not a critical component in the
BALB/C model of colitis. To test this, acute colitis was induced in BALB/C mice by
consumption of 5% dextran sulfate sodium (DSS) in drinking water for 7 days. TACE
inhibition was achieved through twice daily intraperitoneal injection of DPC-333 (10
mg/kg; BSM, Inc.) To determine the effects of TACE inhibition during colitis, BALB/C
mice received the following experimental treatments: Group 1) H2O + vehicle; Group 2)
DSS + vehicle; Group 3) DSS + DPC-333. Although TACE inhibition significantly
reduced colon TNFa levels (p = 0.0172), no significant improvement in disease activity
was observed (p = 0.74), as determined by clinical scoring of bodyweight loss, rectal
bleeding, and diarrhea. Thus, colitis in BALB/C mice does not appear to be TNFa-driven
and an alternative pathway must exist. It is possible that BALB/C mice could represent a
pre-clinical model of primary non-responders to anti-TNFa therapies. Future studies may
use this model to better understand mechanisms of primary non-response in IBD patients.
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INTRODUCTION

Inflammatory Bowel Diseases
Overview. Inflammatory bowel diseases (IBDs), such as Ulcerative Colitis (UC)
and Crohn’s Disease (CD), have been estimated to affect about 2.8 million people in the
United States (Kappelman et al., 2007). These diseases are characterized by recurring
episodes of acute intestinal inflammation resulting in diarrhea, abdominal pain, fever,
blood in the feces, and weight loss. Currently, the etiology of IBDs is unclear, although
the CDC has observed relationships between IBDs and gender, smoking status,
socioeconomic status, and diet, suggesting a role for epigenetics in disease development
(Jenke, 2012). Research attributes disease pathology to an inappropriately activated
immune system leading to increased permeability of the intestinal wall in response to
oxidative stress (Obermeier et al., 1999).
Although research has led to the innovation of therapies and improved
diagnostics, a steady rise in the occurrence of IBDs has been documented in Western
Europe and the United States since the 1960s. Furthermore, IBD patients are more likely
to develop pernicious anemia and lactose intolerance due to intestinal degradation
(Podolsky, 1991). In childhood IBDs, malnutrition is a major cause of stunted growth
(Murch et al., 1991). Likewise, severe UC inflammation has been proven to be related to
neoplasm formation in the colon (Rutter et al., 2004). Treatments aimed at reduction of
inflammation may improve these complications.
However, treating IBDs has proven to be a substantial economic burden. In 2004,
the mean cost of treatments per patient for CD and UC were $8265 and $5066 per year,
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respectively. For both diseases, over 30% of costs were attributed to hospitalization.
Current pharmaceutical therapies are limited by efficacy and cost, and surgical
management via colectomy has been reported to occur in 13.0-16.5% of UC patients at
20 years after diagnosis (Targownik et al., 2012). In 1991, it was reported that
approximately 30% of CD patients required surgical intervention within a year of
diagnosis, while the remainder required surgery at a rate of 5% per year (Podolsky,
1991). Surgical intervention often results in the required use of an ileostomy bag and
increased risk of surgical complications, such as sepsis, colorectal cancers, fistula
formation, intra-abdominal bleeding, and death (Tulchinsky et al., 2003).
IBD Pathogenesis. As earlier stated, the mechanisms of IBD pathogenesis are
poorly understood, yet it is thought that the immune system is inappropriately activated
(Figure 1). In healthy intestines, a luminal stimulus can incite inflammation through
either an antigen-specific immune response or an antigen-nonspecific inflammatory
response. The intestinal immune system will eliminate the stimulus, which halts the
inflammatory response and preserves the integrity of the epithelial barrier. However, in
the disease state, an inflammation develops in the same manner, but stimulus elimination
will either not occur or occur inappropriately, leading to sustained inflammation and
tissue damage. The mucosal barrier integrity is compromised as it becomes more
permeable to intestinal flora and infiltrating inflammatory cells. Thus, a positive feedback
loop ensues, perpetuating the inflammatory response and characterizing the disease state
(Podolsky, 1991). We do not yet understand why IBD patients are being thrown out of
homeostasis, but we think it is because of a dysregulation of the inflammatory response
and the gut microbiota (Figure 2) (Xavier and Podolsky, 2007).

2

Genetic Factors in IBD Development. Throughout the study of IBDs, family
aggregation has long been established. First-degree relatives of IBD patients have a
relative risk of 5-fold or greater. Likewise, IBDs are more prevalent in Ashkenazi Jews
(Podolsky, 1991); however, these conditions are not inherited in a simple Mendelian
pattern, instead, substantial evidence supports a multigenic mode of inheritance (Pokorny
et al., 1997). Furthermore, it is thought that epigenetic alterations may underlie geneenvironmental modifications and constitute causal disease variants.
During chronic inflammation, inflammatory mediators such as cytokines and
reactive oxygen species can induce methylation of various IBD-associated genes through
various mechanisms (Chiba et al., 2012). The investigation of epigenetic mechanisms in
IBD was fueled by the identification of DNMT3A, a methyltransferase gene, as a CD
susceptibility gene. Consequently, altered methylation of a series of genes involved in the
production of cytokines in response to IL-17 has been observed in IBD patients. IL-17 is
secreted by Th17 cells, a subset of CD4+ T cells that are strongly implicated in intestinal
inflammation (Nimmo et al., 2012).
Thus, recent genome-wide searches for IBD susceptibility loci have been
successful in identifying genes that contribute to disease susceptibility (Figure 3)
(Biancheri et al., 2013). These genes have been defined as those whose products may
contribute to functional or structural abnormalities in the GI tract that cause it to be more
susceptible to attack by infection, toxins, or autoimmune activity (Podolsky, 1991).
Novel associations exist between IBD and two genetic markers within the DNA
mismatch repair (MMR) gene MLH1, which has been localized to human chromosome
3p21, a region recently identified as an IBD locus. The protein encoded by MLH1, MutL
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Homolog 1, is one component in a system of seven DNA MMR proteins (Pal et al.,
2008). The DNA MMR system provides fidelity in replication by correcting any postreplication errors that have escaped the proofreading function of DNA polymerase
(Chang et al., 2000). Thus, mutations in DNA MMR genes impart a mutator phenotype to
affected cells in UC, increasing genomic instability. In fact, the lack of efficient DNA
MMR has been shown to lead to carcinoma as well as the production of aberrant proteins
that could incite a localized or systemic autoimmune response (Pokorny et al., 1997).
Other studies have suggested that alterations in the matrix of mucin glycoproteins
may be associated with UC. The dense layer of glycoproteins that coat the colonic
surface is an important component in maintaining the integrity of the intestinal epithelial
barrier (Podolsky and Isselbacher, 1983). One study found a selective reduction of one
population of glycoprotein in UC patients; this alteration persists independently of
inflammatory activity. Similarly, these glycoprotein alterations have been observed in
unaffected monozygotic twins of patients with UC, supporting the idea that genetics may
present a pre-disposing factor in IBDs (Podolsky, 1991).
Furthermore, altered expression of key immunoregulatory genes, such as TNFa
and NOD2, has been reported in the peripheral blood of IBD patients. The TNF gene
maps to the IBD3 susceptibility locus on chromosome 6p21. Deletion of 3’ regulatory
elements from the TNF transcript in mice has been shown to induce a model of CD in
mice due to increased TNFa biosynthesis (van Heel et al., 2002). Likewise, a frameshift
mutation in the NOD2 gene causes increased expression of NOD2, a protein responsible
for inciting an inflammatory response following recognition of bacterial cell wall
components; this up-regulation of NOD2 is associated with susceptibility to CD (Ogura
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et al., 2001). Additionally, a 2012 study of IBD-associated genes provided evidence of
differential methylation of CpG sites within these and other genes that are plausible
candidates in CD pathogenesis (Nimmo et al., 2012).
Diagnosis of IBD. Because the etiology of IBDs remains unclear, the major forms
of IBD, CD and UC, are defined by their clinical, pathologic, radiologic, endoscopic, and
laboratory features. While these diseases share many signs and symptoms, increasing
evidence exists to suggest that CD and UC are two distinct diseases (Podolsky, 1991).
Inflammation in UC presents continuously throughout the large intestine and
rectum, although it is mainly confined to the mucosa and superficial submucosa of the
intestinal wall (Figure 4) (Gore et al., 1996). In contrast, CD inflammatory processes can
occur at any location along the GI tract, including the small intestine. However,
inflammatory lesions are less continuous than those of UC and can penetrate deeper
layers of the intestinal wall (Figure 5) (Podolsky, 1991). Another unique feature of CD is
the development of small, discrete ulcers, termed aphthoid ulcerations. These ulcers have
been discovered prior to onset of inflammatory relapse, give a more accurate assessment
of disease severity, and may herald a relapse in established quiescent disease (Simpkins,
1977).
As stated earlier, diagnosis of IBD is accomplished via assessment of disease
activity, primarily through patient-reported symptoms (i.e. abdominal pain, diarrhea, and
weight loss), laboratory testing, and radiographic and endoscopic evaluation of the colon
mucosa. Endoscopy of the colon, or colonoscopy, along with tissue biopsy, allows for
histological assessment of the colon mucosa. This is pertinent in differentiating between
UC and CD (Leighton et al., 2006). Laboratory biomarkers correlating with leukocyte
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migration into the colon also prove useful as a secondary diagnostic tool (Schoepfer et
al., 2013).
Once an IBD is diagnosed, pharmacological management begins. Results of
disease assessment dictate which pharmacological therapy to use; this is determined by
two general parameters: anatomical location of inflammation and inflammatory severity.
UC practice guidelines, released in 2010 by the Practice Parameters Committee of the
American College of Gastroenterology, establish a classification system for UC
inflammatory severity as mild, moderate, or severe. UC disease severity can be
determined by stool frequency, fecal blood content, erythrocyte sedimentation rate, and
signs of toxicity such as fever, anemia, or tachycardia (Kornbluth and Sachar, 2010).
Current Treatments of Ulcerative Colitis. Along with changes in diet and pain
management, UC patients are usually prescribed medication to reduce inflammation at
the primary site of tissue injury and prevent recurrence. A variety of pharmaceuticals are
currently available for physicians to choose from based on the specific benefits to
individual patients and potential obstacles. Current therapies include anti-inflammatories,
immunosuppressants, and pharmaceuticals aimed at blocking TNFa signaling.
Mesalamine, also known as mesalazine or 5-aminosalicylic acid (5-ASA),
belongs to the aminosalicylate family of anti-inflammatories. Oral administration of the
prodrug sulfasalazine allows for delivery of mesalamine directly to the large intestine
(Azad Khan et al., 1977). In the colon, sulfasalazine is reduced to mesalamine by
intestinal bacteria (Peppercorn and Goldman, 1972). Safety of these pharmaceuticals is
currently under debate, as there are concerns regarding nephrotoxicity and side effects
such as abdominal pain, nausea, and diarrhea (Reviewed by Böhm and Kruis, 2014).
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Corticosteroids prove a more flexible treatment, as they can be administered
orally, by enema, or topically. Corticosteroid medications are commonly used to control
acute inflammation; however, adverse effects include steroid dependency, weight gain,
cataracts, osteoporosis, myopathy, and increased susceptibility to infections (Reviewed
by Lichtenstein et al., 2006). Thus, corticosteroid use has a limited duration and is
determined a failure if resultant in steroid-dependent colitis remission (Benchimol et al.,
2008).
Azathioprine is an oral immunosuppressant currently used to prevent transplant
rejection and as a treatment for rheumatoid arthritis and dermatologic disorders
(Reviewed by el-Azhary, 2003). Azathioprine is also used to induce remission for
steroid-dependent UC patients (Ardizzone et al., 2006). While this steroid-sparing effect
may reduce the need for subsequent surgical resolution, the optimal effects of this
treatment can be delayed for up to four months, making UC management difficult
(Present et al., 1980). Furthermore, there is evidence that treatment with azathioprine may
increase the risk of lymphoma (Kandiel et al., 2005).
Another means of treating steroid-dependent UC is by CsA, an
immunosuppressant that inhibits calcineurin, a protein phosphatase which plays a role in
T cell development; inhibition of calcineurin by CsA blocks T cell function, thus
reducing the immune response (Bram et al., 1993). Like azathioprine, CsA can increase
the risk of malignancy, as well as damage the renal system (Grossman et al., 1996).
Because of these adverse effects, CsA is regarded as a “last-ditch” attempt, reserved for
severe colitis episodes when reduction of inflammation and prevention of colectomy is
urgent.
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Most recently, IBD treatments focus on reducing inflammation by blocking TNFa
signaling. Currently, Infliximab, a monoclonal antibody against TNFa, is the standard in
anti-TNFa therapies. In mild to moderate colitis, Infliximab resolves acute inflammatory
episodes and improves remission time (Rutgeerts et al., 2006). It has also been shown to
improve cases of severe inflammation, although it is less effective in these cases (Olsen
et al., 2009). One study demonstrated that long-term Infliximab treatment induces
mucosal healing, improves long-term outcomes, and reduces the need for surgical
intervention (Figure 6) (Schnitzler et al., 2009). While Infliximab is the current standard
in IBD treatment, its effectiveness may be hindered by development of host antibodies,
resulting in undetectable levels of Infliximab in serum and increased risk of allergic
reaction to Infliximab infusions (Baert et al., 2003).
A review of the current IBD treatments reveals that a quick-acting, long-term
treatment aimed at increasing remission time and reducing inflammatory episodes are
imperative. Anti-TNFa therapies may allow for long-term IBD management, however,
these therapies are last-resort pharmacological approaches to steroid- and thiopurineresistant patients. Furthermore, studies show that anti-TNFa therapies are only effective
in about two-thirds of IBD patients; the remaining one-third of patients demonstrate no
response or a loss of response during treatment (Figure 7) (Papadakis et al., 2005).
Further medical options are necessary to effectively treat this cohort of colitis patients.

Tumor Necrosis Factor a
Overview. Tumor Necrosis Factor a, or TNFa, is a potent inflammatory
mediator originally observed as a host-derived mediator required for endotoxin-induced
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necrosis of tumor cells (Carswell et al., 1975). Since its identification in 1975, overexpression of TNFa has been implicated in many inflammatory pathologies; novel
methods of disease treatment through TNFa inhibition are continuously being explored.
TNFa Structure and Biology. TNFa, a cytokine primarily produced by
activated macrophages and monocytes, plays an important role in the initiation,
regulation, and perpetuation of the inflammatory response (Koss et al., 2000). Overexpression of TNFa has been implicated in many chronic inflammatory diseases, such as
rheumatoid arthritis, multiple sclerosis, insulin-dependent diabetes mellitus, and IBDs
(Plevy et al., 1997).
TNFa is a member of the TNF superfamily, the largest known family of
cytokines. It is initially expressed as an insoluble 26 kDa homotrimeric type II
transmembrane protein (mTNFa). Upon cell stimulation, TNFa Converting Enzyme
(TACE) cleaves the extracellular domain of mTNFa into a 17 kDa soluble isoform
(sTNFa) (Solomon, 1999). Binding of TNFa to a TNFa receptor (TNFR) ultimately
activates downstream signaling pathways that can lead to inflammation (Pasparakis,
1996).
TNFa Receptors. Members of the TNF superfamily act as ligands to activate
corresponding transmembrane receptors of the TNF receptor superfamily. Highly
conserved among TNF ligands, the TNF homology domain (THD) interacts with the
cysteine-rich domains of the TNF receptors (TNFR) (Reviewed by Bodmer et al., 2002).
Activation of TNFRs generally results in one of two opposing signaling pathways: cell
death via apoptosis or cell survival and inflammation (Dempsey et al., 2003).

9

Cell survival or death in response to ligand binding to the receptor depend on the
presence of a death domain in the TNFR and affinity of that receptor for intracellular
signaling proteins. Apoptotic signaling is induced by caspase interaction with TNFR
death domains, while cell survival or inflammation result from TNFR interaction with
TNF receptor associated factor (TRAF) proteins (Dempsey et al., 2003).
So far, two TNFRs that are activated by TNFa have been identified, TNFR1 and
TNFR2 (Brockhaus et al., 1990), both of which bind soluble and insoluble, membranebound TNFa (Locksley et al., 2001). These receptors consist of hydrophobic cysteinerich repeats that form a pre-ligand binding assembly domain (PLAD), which results in
trimerization of the receptors in the absence of TNFa activation (Chan et al., 2000).
Upon interaction with TNFa, the extracellular domains of TNFR1 and TNFR2 are
cleaved into soluble TNFR1/2, a protein that sequesters sTNFa in order to attenuate the
inflammatory response (Wallach et al., 1991).
However, TNFR1 and TNFR2 differ in their activation and downstream signaling.
TNFR1 is fully activated by sTNFa, while TNFR2 is primarily activated by mTNFa and
only partially activated by sTNFa. Also, TNFR1 is expressed ubiquitously across cell
types, while TNFR2 is mainly expressed in immune cells (Grell et al., 1995).
TNFR Signaling. Signal transduction from TNFR1 can result in either cell death
via apoptosis or cell survival and inflammation (Figure 8) (Gupta et al., 2006). Cell death
signaling involves the interaction of TNFR1’s death domain and pro-caspases 8 and 10 to
induce apoptosis. This paper will focus on TNFR signaling for survival and
inflammation, which results in the activation of the transcription factor nuclear factor
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kappa B (NF-kB) and ultimately induces further production of TNFa and other
inflammatory cytokines (DasGupta et al., 2008).
Prior to TNFR1 activation by TNFa, a silencer of death domain (SODD) protein
associates with TNFR1 to mask its death domain, preventing the recruitment of signaling
proteins (Jiang et al., 1999). Upon TNFR1 activation, SODD dissociates and TNFR1associated death domain (TRADD) protein serves as a scaffold for TNFR-associated
factors 1 and 2 (TRAF1/2) and receptor-interacting kinase (RIP) (Hsu et al., 1996).
TRAF2 recruits inhibitor of apoptosis proteins (IAPs) and IkB kinase (IKK). IAPs are
essential for the polyubiquitination of RIP, which is required for IKK activation (Ea et
al., 2006). Subsequently, RIP activates IKK, which in turn phosphorylates the regulator
domain of inhibitor kappa B (IkB) protein, marking it for recognition by an E3 ubiquitin
ligase and degradation (Devin et al., 2000). Initially, IkB sequesters NF-kB in the
cytoplasm by masking its nuclear localization signal (NLS). Degradation of IkB results in
exposure of the NF-kB NLS, allowing the protein to translocate to the nucleus where it
interacts with kB response elements to promote expression of pro-inflammatory
cytokines and anti-apoptotic genes (Wang et al., 1998).
TNFR2 signaling is very similar to that of TNFR1, except that TNFR2 does not
have a death domain, thus it does not require interaction with TRADD and can directly
recruit TRAF proteins upon interaction with TNFa (Rothe et al., 1995). Furthermore,
association of TRAF proteins with TNFR2 allows for induction of either the traditional or
alternative pathways of NF-kB signaling (Rauert et al., 2010). Both pathways result in
nuclear translocation of NF-kB, however, the alternative pathway activates a NF-kB-
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inducing kinase (NIK) mediator to generate free cytoplasmic NF-kB from an inhibitory
precursor.
TNFR signaling via NF-kB acts as a positive feedback mechanism to propagate
the inflammatory response. TNFa activates TNFR which in turn activates the NF-kB
pathway. The NF-kB pathway ultimately promotes expression of pro-inflammatory
cytokines, including TNFa. Newly synthesized TNFa can activate more TNFRs,
perpetuating the inflammatory cycle (Collart et al., 1990).
Soluble TNFRs. In addition to a membrane-associated form (mTNFR), TNFRs
also exist in a soluble form (sTNFR) which is released from mTNFR via the proteolytic
cleavage of its extracellular domains. Previous research has demonstrated that sTNFRs
neutralize the function of TNFa without invoking an inflammatory response, thus
playing a role in the regulation of TNFa activity under physiologic conditions (Spoettl et
al., 2007).
Recent studies suggest that sTNFRs also exhibit immunomodulatory functions.
Through reverse mTNFa signaling, sTNFR is able to induce apoptosis in monocytes
independent of death receptor pathways. It is thought that sTNFR production may
mediate the host response to pathologic states via interacting with TNFa, thus
sequestering it from mTNFRs and preventing induction of inflammatory signaling
pathways. Incidentally, quantification of sTNFRs in plasma provides information about
immune processes leading to a better understanding of various diseases. In fact, sTNFR
levels demonstrate high accuracy in disease prognosis. sTNFR concentrations have been
used as predictive values as they are strongly associated with the clinical stage and
progression of pathologies such as HIV infection and sepsis (Spoettl et al., 2007).
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A 2007 study by Spoettl et al. demonstrated that sTNFR concentrations are higher
in the serum of IBD patients than in healthy controls. sTNFR1 levels were significantly
upregulated in both CD and UC patients, while sTNFR2 concentrations were
significantly increased in CD patients and slightly increased in UC patients. Furthermore,
sTNFR concentrations have been associated with disease activity. A correlation between
increased sTNFR levels in the urine and clinical activity index has been observed
(Hadziselimovic et al., 1995). A 1998 study by Noguchi et al. described a failure to
upregulate sTNFRs in response to enhanced TNFa secretion in the lamina propria
mononuclear cells of IBD patients. This study concluded that an imbalance in
concentrations of TNFa and its natural inhibitors, such as sTNFR, may play a role in the
pathogenesis of IBD. Thus, a better understanding of the mechanisms involved in both
sTNFa and sTNFR release could lead to novel approaches to IBD treatment.

Tumor Necrosis Factor a Converting Enzyme
Overview. Tumor necrosis factor a Converting Enzyme (TACE) is responsible
for cleaving membrane-bound TNFa to create a soluble, mature protein (Figure 9)
(Reviewed by DasGupta et al., 2008). A variety of inflammatory disorders have been
characterized by aberrant TACE activity leading to over-expression of TNFa. As
increased TNFa expression is characteristic of IBDs, it can be inferred that TACE is also
involved in IBD pathology.
TNFa Converting Enzyme. TACE, also known as ADAM17, is a member of the
adamalysin family of metalloproteases, enzymes which require interaction with a metal
ion for activation of the catalytic site (Hooper, 1994). A Disintegrin and Metalloprotease
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(ADAM) proteins are a subtype of adamalysins which contain a metalloprotease and
disintegrin domain (Edwards et al., 2008).
Specifically, TACE contains a pro-domain, catalytic (metalloprotease) domain, a
disintegrin and cysteine-rich region, a transmembrane segment, and a cytoplasmic
segment. The pro-domain acts as an inhibitor of metalloprotease activity. This inactivity
is maintained via interaction of a cysteine residue in the pro-domain with an essential
zinc ion located in the catalytic domain (Van Wart and Birkedal-Hansen, 1990). Removal
of the pro-domain is a pre-requisite for TACE activity (Milla et al., 1999).
The metalloprotease domain of ADAM proteins contains a zinc-binding motif,
which coordinates the zinc with histidine residues, creating the active site of the enzyme.
Although the function of the disintegrin domain in human ADAM proteins is poorly
characterized, it is thought to be responsible for substrate recognition and TACE
maturation (Reddy et al., 2000).
Mechanisms for the regulation of TACE activity are poorly understood. Research
has shown that inhibitors of the MAPK pathway block aberrant increases in TNFa
shedding rate by TACE, however, the mechanism for this is unclear (Fan and Derynck,
1999).
TACE Involvement in Pathologic Inflammation. As stated earlier, a variety of
inflammatory disorders have been characterized by aberrant TACE activity. For example,
increased TACE expression in peripheral monocytes has been observed in patients with
early systemic sclerosis, while rheumatoid arthritis patients exhibit increased TACE
mRNA levels in cartilage (Bohgaki et al., 2005; Patel et al., 1998).
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The pivotal role of TACE in inflammatory signaling was clarified in a study of
mice with cleavage-defective mTNFa. These mice displayed attenuated inflammation,
similar to TNFa knockout mice, demonstrating that mTNFa shedding is necessary for
the propagation of inflammation (Ruuls et al., 2001). Further research has shown that
reducing sTNFa levels through TACE inhibition allows for regulation of the
inflammatory response. TACE inhibition was also shown to improve survival of mice
against a lethal dose of lipopolysaccharide (LPS), a component in bacterial cell walls that
induces inflammation (Figure 10) (Newton et al., 2001).
TACE has also been shown to play a role in IBD pathology. UC patients display
increased TNFa cleavage potential, indicating increased functional TACE capacity
(Brynskov et al., 2002). Furthermore, biopsies of inflammatory lesions in the intestinal
epithelia of CD patients exhibited increased TACE expression (Cesaro et al., 2009).
Thus, TACE inhibition, with the purpose of reducing TNFa levels may prove a viable
method of IBD treatment.
History of TACE Inhibition. In the attempt to discover an effective TACE
inhibitor, a variety of chemicals have been proposed and developed. Initially scientists
began testing matrix metalloproteinase (MMP) inhibitors and found that, because TACE
shares catalytic site structure with MMPs, MMP inhibitors also inhibited TACE activity.
Because both TACE and MMPs are involved in normal physiological processes, the lack
of TACE-specificity caused these drugs to exhibit toxicity (Yocum et al., 1999). Thus,
the next step was to observe the electronic, structural, and kinetic differences between
TACE and MMPs to design TACE-specific inhibitors.
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Indeed, comparison of the crystal structures of TACE and MMPs led to the
discovery of structural differences. The fact that the S1’ pocket of TACE is longer and
narrower than that of MMPs has formed a basis for designing selective TACE inhibitors,
such as anthranilate-based compounds (Duan et al., 2002). Furthermore, modifications to
the P1’ and P2’ residues have been found to confer specificity on TACE inhibitors. For
example, macrocyclic inhibitors, formed by joining the P1’ and P2’ groups of succinatebased TACE inhibitors to form a cyclic structure, were found to be more selective
towards TACE over MMP by 100-fold (Holms et al., 2001).
Based on these discoveries, many compounds based on various chemical classes
have been developed as selective TACE inhibitors and TACE inhibition during
inflammatory disorders has been explored in pre-clinical animal models of rheumatoid
arthritis (Reviewed by Moss et al., 2008). In a study of murine rheumatoid arthritis
models, TACE inhibition significantly suppressed release of TNFa into serum.
Furthermore, histological evaluation of the joints showed normal joint structure following
TACE inhibition; prior to TACE inhibition, joints were plagued with lesions and
inflammation (Newton et al., 2001).
Although TACE inhibition was successful in pre-clinical models, concerns about
liver toxicity and lack of efficacy have blocked progression of TACE inhibitors past
Phase II clinical trials (Reviewed by DasGupta et al., 2008).
TACE Inhibition Through DPC-333. DPC-333, also known as BMS-561392, is
a TACE-specific, small molecule inhibitor developed in 2002 (Grootveld and
McDermott, 2003). Upon finding that DPC-333 was 100-fold more selective of TACE
over MMPs, Bristol-Myers Squibb Company claimed that DPC-333 was unlikely to have
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many adverse effects due to its non-antigenic structure and oral administration; although
they did warn that close monitoring was required with treatment. Pre-clinically, DPC-333
was found to have good bioavailability in primates and dogs (54%) and reasonable
bioavailability in rats (16%) (Grootveld and McDermott, 2003).
In Phase I clinical trials, DPC-333 was found to be well tolerated by humans at a
dose rage of 15 to 530 mg (Grootveld and McDermott, 2003); however, 53% of DPC-333
recipients (n=6) and 40% of the placebo group (n=20) reported adverse effects, taste
disturbance being the most commonly reported adverse experience (Qian et al., 2007).
Although the compound demonstrated high potency and selectivity toward TACE, DPC333 caused liver toxicity issues, resulting in withdrawal from Phase II clinical trials
(Reviewed by Moss et al., 2008).
While adverse effects were observed in humans, continued study of the effects of
DPC-333 on TNFa production in mice could lead to advances in inflammatory disease
research. Oral administration of DPC-333 to mice inhibited LPS-induced TNFa
production (Figure 11) (Sharma et al., 2012). Although mice have low oral bioavailability
(<20%), they have 98% bioavailability after intraperitoneal (IP) injection of 11 mg/kg
bodyweight. Furthermore, IP injection of DPC-333 in mice is rapidly absorbed and
maximum plasma concentration is reached at 0.1 hours after injection (Qian et al., 2007).

Selecting a Mouse Model of Colitis
Overview. Although the etiology of IBD remains unclear, current knowledge of
the mechanisms that underlie IBD pathology can be attributed largely to the study of
colitis in mice. Mice represent a readily available and flexible model of study; the many
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methods of disease induction alone provide a large variety of study designs. The multiple
mouse strains available to choose from add further variety as each strain exhibits
differences in response to disease induction methods and disease activity. Murine models
of colitis have been organized into four main categories based on method of disease
induction (Blumberg et al., 1999).
Spontaneous Colitis Models. Currently, only two mouse models that
spontaneously develop colitis have been described: the SAMP1/Yit model and the
C3H/HeJBir mouse. SAMP1/Yit mice were originally developed from AKR mice, which
were bred for the purpose of studying senescence. By chance, these mice also develop
mucosal inflammation with features comparable to those of CD. The C3H/HeJBir mouse
lacks the toll-like receptor 4, and so is unresponsive to LPS. These mice spontaneously
develop colitis at 3-4 weeks of age (Hoffman et al., 2002). Although spontaneous colitis
is uncommon in mice, with knowledge of their genetic background these models offer the
possibility of defining the genetic factors that lead to IBD (Blumberg et al., 1999).
Genetically Engineered Colitis Models. The category of genetically engineered
colitis models consists of those with genetic alterations produced by gene targeting or the
induction of a transgene. The major advantage of these models is that they allow the
study of a particular gene product and its role, or lack thereof, in colitis development and
progression (Blumberg et al., 1999). Study of these mice allowed for characterization of
the immune network of IBD-associated genes (Mizoguchi & Mizoguchi, 2010).
Currently, several KO mouse strains have been developed which lack IBD-associated
genes, some of which spontaneously develop colitis while others require additional
immune or environmental factors to fully elicit colitis development (Mizoguchi &
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Mizoguchi, 2010). For example, Mdr1a-/- mice lack the murine multiple drug resistance
gene for P-glycoprotein 170 and spontaneously develop colitis at around 12 weeks of age,
highlighting a role for MDR genes in IBD pathology (Wilk et al., 2005). Models that do
not develop colitis spontaneously allow for in-depth study of a desired gene product. For
example, administration of DSS to a MMP9-/- mouse revealed a role for MMP9 activation
in colitis-associated neutrophil infiltration of the intestinal mucosa (Munakata et al.,
2015).
Transfer Models of Colitis. A third category of colitis models involves the
development of colitis following transfer of particular cell populations into a neutral host.
It has long been established that shifts in microbiota composition can induce colitis
(Bloom et al., 2011). Studies involving mice with IBD-associated defects further
demonstrated the importance of microbiota composition in colitis development when KO
mice raised under germ-free conditions failed to develop colitis. This discovery led to the
development of colitis transfer models to differentiate between bacterial populations
associated with colitis development or prevention. For example, transfer of various
Lactobacillus species prevented colitis development in IL-10-deficient mice living under
specific pathogen-free conditions. In contrast, these mice develop colitis following
introduction of Helicobacter hepaticus (Blumberg et al., 1999).
Exogenously-induced Colitis Models. The development of colitis following
exposure of wild type mice to an exogenous agent that induces an immune response
comprises the fourth category of colitis model. The advantage of this category is the
ability to observe relationships between particular immune responses and histopathologic
reaction, as well as immunopathogenesis and treatment (Blumberg et al., 1999).
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Commonly, colitis is induced by two different chemicals: dextran sulfate sodium (DSS)
and trinitrobenzene sulfonic acid (TNBS). Consumption of DSS in drinking water results
in a model of colitis relevant to clinical UC, while intra-rectal administration of TNBS
induces a model of colitis comparable to CD (Scheiffele & Fuss, 2002). Both chemicals
are thought induce colitis by causing direct injury to intestinal epithelia (Perse & Cerar,
2012).
Additionally, a model of colitis comparable to clinical UC can be induced by IP
injection of an agonistic CD40 monoclonal antibody to B- and T-cell-deficient mice
(Munakata et al., 2015). CD40 is a type I transmembrane protein that belongs to the
TNFR superfamily and is ubiquitously expressed on the surface of immune cells. The
CD40/CD40L system allows for signaling between immune cells that, when stimulated in
excess, results in an autoimmune inflammatory response dependent on the release of proinflammatory signaling molecules (Danese et al., 2004).

A DSS-Induced Colitis Mouse Model
Overview. Previous research has demonstrated that consumption of dextran
sulfate sodium (DSS) in a murine model produces a clinically relevant model of colitis;
the induced disruption of the colon mucosa is similar to clinical colitis in humans (Figure
12) (Perse and Cerar, 2012). Supplementing the animal’s drinking water with DSS for 7
days results in erosion of the colon mucosa, dysplasia, shortening of the colon, diarrhea,
fecal blood content, and weight loss (Okayasu et al., 1990). The mechanism by which
DSS induces inflammation is not well understood, however, mucosal barrier degradation
may result from direct toxicity to intestinal epithelia (Dieleman et al., 1994). It has also
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been reported that TNFa and interferon-g (IFN-g), cytokines involved in the perpetuation
of chronic DSS-induced colitis, cause excessive nitric oxide activity which could be the
effector mechanism (Obermeier et al., 1999). Due to the ease of administration and rapid
development of colitis, the DSS murine model is beneficial in studying IBDs (Wirtz et
al., 2007). Furthermore, severity of colitis in response to DSS is strain dependent, which
could highlight a role for genetic background in the development of inflammatory
diseases (Melgar et al., 2005).
Tissue Destruction in Colitis Development. The primary function of the
intestinal epithelium is to serve as a selectively permeable barrier between internal and
external environments through which nutrients, ions, and water are absorbed and
secreted. When the barrier is intact, tight junctions limit solute flux to create transepithelial gradients which drive passive paracellular transport of ions and water (Turner,
2009). Absorption of nutrients occurs through coupling of organic solutes (i.e. sugars and
amino acids) to Na+ transport across the small-intestinal epithelial lining (Figure 13). The
organic solutes then move from enterocytes to blood via basolateral membrane carriers
operating independently of ion transport (Field, 2003).
Physical features of the epithelial barrier, such as crypts, villi, and surface cells,
are responsible for absorption and secretion (Field, 2003). The direct damage to the
epithelial lining caused by DSS exposure disrupts these features, resulting in diarrhea and
bodyweight loss due to malabsorption. This correlates to human IBD in that bacterial
flora, food products, and inflammation can alter secretion and absorption through
disrupting the integrity of crypts, villi, and surface cells (Field, 2003). Additionally,
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apoptosis in response to cell damage reduces intestinal surface area and thus, decreases
the capacity for absorption (Weber & Turner, 2007; Owens & Greenson, 2007).
Furthermore, the epithelial damage caused by DSS consumption results in
increased intestinal permeability, a characteristic observed in human IBD.
Physiologically, tight junctions seal the paracellular pathway between epithelial cells,
restricting molecule passage based on size and charge. Destruction of tight junctions
opens the paracellular pathway, increasing intestinal permeability and allowing
infiltration of immune cells into the colon mucosa. Thus, inflammation of the colon
mucosa, or colitis, results (Field, 2003).
Pro-inflammatory Effects of TNFa in Colitis Development. Previous research
has demonstrated that, while DSS causes direct tissue damage, the over-expression of
TNFa drives colon inflammation in DSS-induced colitis. It has long been established that
TNFa plays a critical role in pathologic inflammation by recruiting inflammatory cells,
inducing edema, promoting granuloma formation, and activating the coagulation cascade.
TNFa has been shown to induce intestinal epithelia to express cell adhesion molecules
and secrete chemokines; these processes result in the influx of inflammatory cells. Once
recruited to the mucosal epithelium, monocytes and T-cells are further activated by
TNFa to secrete pro-inflammatory cytokines and tissue degrading enzymes (Baugh &
Bucala, 2001).
The importance of TNFa in the propagation of inflammation was highlighted by
the TNFDARE/WT mouse model. Deletion of a repeated AU-rich motif in the 3’untranslated region of the TNF encoding gene enhanced mRNA stability of TNFa,
resulting in mice that spontaneously develop a severe CD8+ T cell ileitis resembling
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human CD. Studies of this mouse attribute pathology to local expression of proinflammatory cytokines, such as TNFa, likely produced by infiltrating immune or
epithelial cells (Baur et al., 2011).
Additionally, multiple studies by Wang et al. have characterized a mechanism by
which TNFa contributes to barrier dysfunction by up-regulating myosin light chain
kinase (MLCK) expression (Figure 14). Phosphorylation of myosin II regulatory light
chain (MLC) by MLCK has been shown to be involved in physiological and pathological
tight junction regulation. Treatment of intestinal epithelial monolayers with IFN-g and
TNFa increased MLC phosphorylation and increased intestinal permeability, leading to
the conclusion that barrier dysfunction is inducible through IFN-g and TNFa production
(Wang et al., 2005).
Cytokine Expression in Two Models of DSS-Induced Colitis. The C57/BL6
and BALB/C mouse models have both been used in the pre-clinical study of colitis. After
5 days of consuming 5% DSS in drinking water, both mouse models developed acute
colitis; however, when no longer exposed to DSS, C57/BL6 mice progressed to severe
chronic inflammation, while BALB/C mice were symptom-free within two weeks
(Melgar et al., 2005).
Cytokine quantification revealed that IL-1b, IL-12 p70, and IL-17 were
progressively upregulated following chronic development in C57/BL6 mice; these
cytokines are involved in T cell-mediated immunity, suggesting that the development of
chronic colitis is T cell-driven. In contrast, during the acute phase of the disease,
BALB/C mice demonstrated up-regulation of cytokines involved in macrophage
activation (IL-1, IL-6, IL-18, and G-CSF); these levels were decreased coinciding with
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disease resolution. Furthermore, production of IFN-g, a macrophage activator produced
by T cells, was low in BALB/C during the acute phase while high in C57/BL6,
suggesting that the acute response in BALB/C mice is macrophage-driven (Figure 15)
(Melgar et al., 2005).
As it has been previously established that multiple loci affect the disease in both
mice and humans, Melgar et al. concluded that these results demonstrate the effect of
genetics on the development and severity of colitis (Melgar et al., 2005).
TACE Inhibition in Colitis Mouse Models. As TACE has become a target of
interest in colitis treatment, TACE inhibition has been studied in both C57/BL6 and
BALB/C mice. A study by Sharma et al. demonstrated dose-dependent improvement of
colitis in C57/BL6 mice through administration of a selective TACE inhibitor. The
authors were able to show improved disease activity index (DAI) of colitis through
evaluation of percent bodyweight loss, colon length, fecal blood content, and stool
consistency (Figure 16). Following a 5-day regimen of 3.5% DSS paired with oral
administration of the TACE inhibitor to female C57/BL6 mice for 7 days, the cytokine
quantification of colon-cultured media exhibited a decrease in serum TNFa levels
(Sharma et al., 2014).
Concurrently with Sharma et al., Maddox and Haines examined the effects of
TACE inhibition in a BALB/C model of colitis (5% DSS consumption for 7 days). These
results show no significant difference in disease activity between DSS mice that received
the TACE inhibitor versus a control group (Figure 17); however, Maddox and Haines did
demonstrate bioactivity of the TACE inhibitor in a model of systemic inflammation due
to LPS injection (10 mg/kg bodyweight) (Figure 18) (Maddox, 2015). Further study is
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necessary to determine the cause of failure of TACE inhibition to improve disease
activity in BALB/C mice. It is possible that the acute colitis observed in BALB/C mice
could effectively act as a pre-clinical model for studying IBD patients (1/3) who do not
respond to anti-TNFa therapies.

Efficacy of Anti-TNFa Therapies for IBD Treatment
Overview. Modulating TNFa activity has been shown to ameliorate disease in
many inflammatory pathologies, such as rheumatoid arthritis and IBD. Down-regulation
of TNFa activity has been accomplished in three main ways: antibody-induced
neutralization of TNFa, non-specific TNFa inhibition, and inhibition of TNFa
processing through blockage of TACE activity. While initially successful, these
treatments have demonstrated a loss of response over time, as well as potentially serious
side effects. The likelihood of these approaches to improve long-term outcomes of IBD
depends upon whether TNFa plays a critical role in the condition (Baugh & Bucala,
2001). Efficacy, or the ability of a therapy to produce the desired result, is a major
determinant of the therapy’s success in treating disease. Anti-TNFa therapies have been
shown to be efficacious in inflammatory pathologies in which TNFa is the driving force;
however, a decrease or lack of efficacy, as seen in loss of response and non-response,
could be explained should an alternative pathway drive inflammation in some cases of
IBD.
Mechanisms for Loss of Response. It has been observed that approximately onethird of IBD patients exhibit a lack of response to anti-TNFa therapies (Papadakis et al.,
2005). In a Danish study of 759 IBD patients, ~70% were responders, ~13% were partial
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responders, and ~17% were non-responders (Bank et al., 2015). Furthermore, 23-46% of
IBD patients demonstrate a loss of response to anti-TNFa treatments over time (Roda et
al., 2016).
The definition of loss of response, or secondary non-response, is initial response
to therapy after an induction regimen followed by loss of response during maintenance
treatment. A common mechanism behind loss of response to anti-TNFa is the
development of immunogenicity due to the development of host antibodies against the
TNFa agonists. These antibodies either prevent binding of TNFa to TNFR or hasten
drug clearance. Studies have demonstrated that the use of immunosuppressive therapy
along with Infliximab results in reduced anti-drug antibody formation. Furthermore, pretreatment with corticosteroids led to significantly less patients who developed antibodies
(26%) compared with those that did not receive steroid treatment prior to Infliximab
therapy (42%) (Roda et al., 2016).
The accepted clinical definition of primary non-response (PNR) is a lack of
improvement of clinical signs and symptoms with induction therapy. Several factors
seem to negatively influence the risk of PNR, such as disease longer than 2 years, small
intestinal involvement, smoking, C reactive protein, and genetic mutations. Evidence
suggests that optimization of the dosing regimen and combination therapy can reduce
PNR occurrence (Figure 19); however, this involves escalating dosage and close drug
monitoring. Current opinions on mechanisms of PNR involve symptoms other than active
inflammation, early immunogenicity, or non-TNFa-mediated inflammation (Roda et al.,
2016).
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Hypothesis and Rationale
The involvement of TNFa in acute IBD in BALB/C mice will be studied in this
research project as a continuation of the research in the Morris lab. Based upon previous
data in the Morris lab, the hypothesis states that TNFa is not a critical component in the
development of colitis in BALB/C mice. It has been established that one-third of IBD
patients do not respond to anti-TNFa therapies, thus, if our hypothesis is correct,
BALB/C mice could represent a pre-clinical model for primary non-responders.
In studies conducted by Maddox, very low levels of TNFa were measured at 2-6
pg/mg total protein; however, colon tissue was homogenized ex-vivo in the absence of
tissue culture (Figure 20). Previous studies utilized a tissue culture technique to allow for
further cytokine production which resulted in more significant TNFa levels. Thus, in
order to determine whether TNFa production is involved in this model, this study will
utilize a tissue culture system to determine the impact of the TACE inhibitor.
Only the distal portion of the colon will be used for quantification of TNFa
levels, as Maddox and Haines demonstrated that inflammation is most active in this
region, especially regarding IL-6 production. The distal colon will be removed and
cultured for 24 hours to allow for further production of TNFa. Plasma TNFa levels will
then be quantified using the MagPix system.
Acute colitis will be induced by administration of 5% DSS in drinking water for 7
days. The TACE inhibitor DPC-333 will be supplied by Bristol-Myers Squibb, Inc.;
approval for use of DPC-333 by Bristol-Myers Squibb was acquired April 8, 2013. The
drug, dissolved in 25 mM citric acid saline, will be delivered twice daily via IP injection,
using a 1 mg/kg bodyweight ratio.
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As demonstrated by Melgar et al., the mechanisms of acute colitis differ from
those of chronic disease. Thus, it may be these differences that cause one-third of IBD
patients to be unresponsive to anti-TNFa treatments. Determining the involvement of
TNFa in acute colitis through study of BALB/C mice may lead to a better understanding
of the disease and provide insights into mechanisms of treatment in human colitis.
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Figures

Figure 1. Potential pathogenic relations in Inflammatory Bowel Disease. In the normal
state, shown in Panel A, the intestinal lumen comes into contact with a variety of
substances that might stimulate either a specific immune response, a nonspecific
inflammatory response, or both. This mechanism has the potential to auto-amplify, but is
counterbalanced by the mucosal barrier, which limits access of luminal constituents to the
intestinal epithelium, and by feedback mechanisms that down-regulate the immune and
inflammatory responses after eliminating the stimulus. In the disease state, shown in
Panel B, fundamental differences in the integrity of the mucosal barrier and/or in the
regulatory mechanisms of the immune system may contribute to sustained inflammation,
regardless of stimulus elimination; this results in tissue destruction and subsequent
inflammatory bowel disease (Reproduced with permission from The New England
Journal of Medicine, Podolsky, 1991. Copyright Massachusetts Medical Society).
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Figure 2. Several IBD susceptibility gene products modulate host-cell functional
responses to microbial flora. Panel (a) illustrates cell-specific NOD2/CARD15 signaling
pathways. In intestinal epithelium, bacterial cell wall components are recognized by the
leucine-rich repeats domains of NOD2, which leads to activation of the NF-kB pathway.
Panel (b) denotes potential roles for autophagy in IBD. Autophagy provides a mechanism
of response among cells to limit the harmful effects of exogenous and endogenous
stressors and thus, is essential for homeostasis. This diagram denotes the stages at which
autophagy may play a role in acute inflammation and the pathogenesis of IBD (Reprinted
with permission from Macmillan Publishers Ltd: Nature, Xavier RJ and Podolsky DK,
2007).
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Figure 3. IBD-associated genes. Many genes have been identified as IBD susceptibility
loci, including genes for cytokine production, DNA mismatch repair, mucin
glycoproteins, and immunoregulation (Reprinted from Trends in Immunology 34(11),
Biancheri et al., The challenges of stratifying patients for trials in inflammatory bowel
disease, 2013, with permission from Elsevier).
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Figure 4. Endoscopic and histologic features of Ulcerative Colitis. In panel A,
colonoscopy of the sigmoid colon of a patient with severe UC depicts diffuse mucosal
ulceration associated with mucopurulent exudate and mucosal bleeding. In panel B,
histologic analysis demonstrating typical features of UC, including mucosal ulceration,
formation of crypt abscesses (arrow indicates a typical crypt microabscess) and depletion
of goblet cells. Additionally, chronic inflammation is present, confined to the mucosal
and submucosal layers (Reproduced with permission from The New England Journal of
Medicine, Podolsky, 1991. Copyright Massachusetts Medical Society).
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Figure 5. Endoscopic and histologic features of Crohn’s Disease. In panel A,
colonoscopy of the sigmoid colon of a patient with CD depicts the patchy nature of the
inflammatory process; irregular ulcers are separated by mucosa that has been relatively
spared. In panel B, histologic analysis illustrates transmural inflammation with the
formation of deep linear ulcers (arrow in inset denotes a typical non-caseating granuloma
(Reproduced with permission from The New England Journal of Medicine, Podolsky,
1991. Copyright Massachusetts Medical Society).
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Figure 6. Long-term clinical benefit of Infliximab treatment. Panel A illustrates the longterm clinical benefit with respect to mucosal healing during Infliximab treatment (n=214)
(Reproduced with permission from Inflammatory Bowel Disease, Schnitzler et al., 2009).

Figure 7. Responses to Adalimumab treatment among CD patients with attenuated
response to Infliximab. Approximately one-third of CD patients demonstrate no response
to anti-TNFa therapies (Adapted from Papadakis et al., 2005 with permission from
Blackwell Publishing: American Journal of Gastroenterology).
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Figure 8. TNFR1-induced pathways. Formation of complex I upon activation by TNFa
leads to NF-κB activation and, ultimately, cell survival through inflammation. Formation
of complex II upon activation by TNFa leads to cell death via apoptosis (Reproduced
with permission from BioMed Central Ltd: Immunity and Ageing, Gupta et al., 2006).
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Figure 9. Activation and inhibition of TNFa and TNFR. Membrane-bound proTNFa is
cleaved by TACE, releasing mature, soluble TNF (sTNFa). Infliximab/adalimumab and
Etanercept represent current pharmaceuticals directed at reducing sTNFa levels, thus
preventing activation of TNFR1/2 (Reprinted from Bioorganic & Medicinal Chemistry,
17(2), DasGupta et al., Current perspective of TACE inhibitors: A review, 2009, with
permission from Elsevier).
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Figure 10. Effects of TACE inhibition or Etanercept administration on LPS-induced
cytokine production. TACE inhibition resulted in significant reduction of plasma TNFa
levels, suggesting TACE inhibition may prove a viable method of treatment for
inflammatory pathologies. Etanercept is a decoy receptor that binds and neutralizes TNFalpha. However, it has been demonstrated to increase plasma TNF-alpha concentrations
by prolonging the half-life of TNF-alpha and reducing its clearance. Blocking TNF-alpha
upstream of membrane shedding via TACE inhibition would eliminate this problem by
preventing soluble isoforms in the plasma (Reproduced from Biology of TACE
inhibition, Newton et al., 60:30, 2001, with permission from BMJ Publishing Group Ltd).
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Figure 11. Effect of various concentrations of DPC-333 on LPS-induced TNFa levels in
mice. Panel A illustrates significant reduction in sTNFa with increasing DPC-333
concentrations. Panel B illustrates significant increases in mTNFa levels with increasing
DPC-333 concentrations. Taken together, this data indicates reduction in TNFa
processing and successful inhibition of TACE (Reprinted from European Journal of
Pharmacology, 701(1), Sharma et al., Blockade of tumor necrosis factor-alpha converting
enzyme (TACE) enhances IL-1B and IFN-gamma via caspase-1 activation: A probable
cause for loss of efficacy of TACE inhibitors in humans?, 2012, with permission from
Elsevier).

Figure 12. Schematic of DSS-induced colitis. Various factors regarding the DSS itself,
the host, and the environment can influence the susceptibility, onset, severity, and
responsiveness to DSS-induced colitis (Reproduced from Journal of Biomedicine and
Biotechnology; Perse M, Cerar A. Dextran sodium sulphate colitis mouse model: traps
and tricks. 2012, with permission from Hindawi Publishing Corporation).
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Figure 13. Intestinal absorptive cell. Nutrient absorption is coupled to sodium transport
across the intestinal epithelial lining (Republished with permission of The American
Society for Clinical Investigation from Intestinal ion transport and the pathophysiology of
diarrhea, Field M, vol 111, 2003; permission conveyed through Copyright Clearance
Center, Inc).
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Figure 14. Pathogenesis of barrier dysfunction in IBD. TNFa affects transcriptional and
enzymatic activation of myosin light chain kinase (MLCK) resulting in acute and rapidly
reversible intestinal epithelial barrier defects (Reproduced from Inflammatory bowel
disease: is it really just another break in the wall?, Weber CR, Turner JR, 56:6-8, 2007
with permission from BMJ Publishing Group Ltd).
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Figure 15. Cytokine production in acute, chronic and recovery phases of DSS-induced
colitis in C57/BL6 and BALB/C mice. Levels of IL-1b (A), IL-12 p70 (B), IL-12 p40
(C), IL-17 (D), and IFN-g (E) were analyzed for each strain (Reproduced with permission
from The American Journal of Gastroenterology and Liver Physiology, Melgar et al.,
2005).
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Figure 16. Effect of TACE inhibition on DSS-induced colitis. Colitis was induced in
C57/BL6 mice by consumption of 3.5% DSS in drinking water for 5 days. Compound
11p, CsA, or vehicle treatments were administered daily starting on day 1 of DSS
administration and ending on day 7. Animals were observed daily for body weight and
DAI. On day 10 animals were sacrificed and colon lengths measured. These data
demonstrate overall TACE inhibition reduces disease symptoms when compared with
diseased control groups (Reprinted from Involvement of TACE in colon inflammation :
A novel mechanism of regulation via SIRT-1 activation, 66(1), Sharma et al., 2014, with
permission from Elsevier).
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Figure 17. TACE inhibition and average disease activity index during development of
colitis in BALB/C mice. No significant difference in DAI was observed between DSS
mice that received the TACE inhibitor versus the control group (Reproduced with
permission from Missouri State University, Maddox, 2015).

Figure 18. Plasma TNF and TACE inhibition during LPS challenge in BALB/C mice.
Bioactivity of the TACE inhibitor was confirmed in a model of LPS-induced systemic
inflammation (Reproduced with permission from Missouri State University, Maddox,
2015).

43

Figure 19. Management of patients with loss of response to anti-TNF therapies
(Reproduced from Roda G, Loss of response to anti-TNFs: definition, epidemiology, and
management; 2016, with permission from Nature Publishing Group).
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Figure 20. Effect of TACE inhibition on colon TNF without tissue culture. TACE
inhibition had no effect on colon TNF-alpha concentrations. Maddox removed colon
tissue, homogenized it, then took the supernatant for quantification. Colon TNF-alpha
concentrations were quantified at 2-6 pg/mg total protein. These levels are so low as to be
insignificant and represent a weakness of the Maddox and Haines study (Reprinted from
Tumor necrosis factor alpha converting enzyme during acute colitis in mice: a regional
analysis, Maddox, 2015, with permission from Missouri State University).
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MATERIALS AND METHODS

Cohort Establishment and Induction of Colitis
Animal care followed the Missouri State University guidelines for
experimentation with animals and was approved by the Institutional Animal Care and
Use Committee of Missouri State University on April 29, 2016 (ID# 16-027.0-A). Acute
colitis was induced in male BALB/C mice by supplementing drinking water with 5%
DSS weight/volume. The 5% DSS water was replaced with fresh DSS solution every two
days.

Dosing of DPC-333
DPC-333 was dissolved in 25 mM citric acid (CA) saline at 1 mg DPC-333 per 1
mL CA saline. Previous studies established CA saline as the vehicle for DPC-333 and
performed qualitative solubility tests to determine appropriate CA concentrations (Kim et
al., 2008; Maddox, 2015). DPC-333 was administered at 10 mg/kg bodyweight by
intraperitoneal (IP) injections of 1 mg/mL DPC-333. Previous investigation of
pharmacodynamics of DPC-333 demonstrated that 10 mg/kg bodyweight IP injection was
found to effectively block TACE activity and production of sTNFa in vivo (Figure 21)
(Qian et al., 2007).

Study Design
Three cohorts (n=6-7) of mice were used in this study to generate one control
group and two disease groups: 1) H2O + vehicle, 2) 5% DSS + vehicle, 3) 5% DSS +

46

inhibitor (Figure 22). A second control group, H2O + inhibitor, was not generated due to
previous study in this lab (Maddox, 2015). Each mouse received twice daily IP injections
of either DPC-333 (10 mg/kg bodyweight) or an equivalent volume of vehicle (25 mM
CA saline). DSS was administered for 7 days before tissue collection under isoflurane
anesthetization and animal sacrifice by isoflurane overdose and cervical dislocation. Food
and water consumption were monitored daily. Additionally, clinical scoring parameters,
including bodyweight, stool consistency, and presence of blood in the stool and at the
anus, were evaluated daily.

Single Blinding of Control and Experimental Groups
Cohort treatments were blinded from assessor. Each mouse was randomly
assigned to a cohort. Conical vials were filled with either 5% DSS in drinking water or
tap water by an assistant and installed in the appropriate cage without assessor knowledge
of vial contents. Syringes were filled with either inhibitor or vehicle by assistants and
labeled with mouse identifier. The assessor then injected the appropriate mouse with the
corresponding syringe without knowledge of contents.

Assessment of Disease Activity
Disease activity was evaluated through daily recording of bodyweight, food and
water consumption, stool consistency, and rectal bleeding. A disease activity index
(DAI), adapted from Cooper et al., was calculated by assigning scores for parameters
analogous to clinical presentation of IBD in humans.
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DAI was calculated as the sum of DAI scores resulting in the total DAI score
ranging from 0 (unaffected) to 12 (severe colitis) (Table 1). Score parameters included
weight loss (-1 = 1-5% weight gain, 0 = none, 1 = 1-5% weight loss, 2 = 5-10% weight
loss, 3 = 10-15% weight loss, and 4 = >15% weight loss), stool consistency (0 = normal,
2 = loose stools, 4 = watery diarrhea), and bleeding (0 = no bleeding, 2 = slight bleeding,
4 = gross bleeding).

Tissue Sample Collection and Culture
Distal colon specimens were collected from mice anesthetized under isoflurane.
Specimens were placed in cold saline, opened longitudinally, and cleared of fecal matter.
Specimens then underwent three washing steps with ice cold saline, placed in 1 mL of
complete RPMI medium 1640 [10% FBS vol/vol, 100 IU penicillin, 100 µg/mL
streptomycin, 2 mM L-glutamine], and minced. Medium containing minced specimen
was then transferred to culture plates and incubated for 24 hours at 37°C. Following
incubation, culture media was transferred to a microcentrifuge tube and centrifuged at
16.2 RCF for 10 minutes at 4°C. Aliquots of supernatant were then taken for TNFa
quantification (Protocol adapted from Sharma et al., 2014).

TNFa Quantification
Tissues were homogenized in lysis buffer compatible with EMD Millipore
Milliplex Mouse TNFa Magnetic Bead Panel kit for use with the Luminex MagPix
singleplex system. Protocol for plasma and tissue preparation as outlined by the kit
instructions were followed.
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Luminex xMAP kits provide magnetic beads conjugated with bead-specific
antibodies for use in a multiplex immunoassay similar to the enzyme-linked
immunosorbent assay (ELISA) concept of protein quantification (Luminex, 2011). The
bead provides a solid surface for building the assay. A bead-conjugated primary antibody
is incubated with sample containing an unknown concentration of analyte. Subsequent
incubations are performed to attach a secondary antibody followed by a reporterconjugated tertiary antibody (streptavidin-phycoerythrin).
The MagPix multiplex system is a LED-based system which detects individual
bead identity through excitation at 635 nm and identification of bead-specific
fluorescence (Figure 23). Primary antibodies for TNFa are conjugated to beads with a
specific fluorescence range. Simultaneously, the fluorescent label of the immunoassay is
excited with a green LED at 525 nm and the intensity of fluorescent emission is
quantified. In this manner, the MagPix system is capable of quantifying TNFa; median
fluorescence intensity (MFI) for TNFa is then used to interpolate assay sample
concentration from a standard curve.
For the quantification of TNFa, 25 µL of colon tissue homogenate samples
diluted to 2-5 µg/mL were analyzed. Standards were generated from serial dilution of
10,000 pg/mL reconstituted Mouse Cytokine Standard, resulting in 6 standards down to
3.2 pg/mL. Experimental and standard samples were incubated overnight with 25 µL
antibody conjugated beads. Tris lysis buffer was used as a background matrix with tissue
homogenate assays. Samples were then incubated with a secondary antibody for one
hour, followed by an hour-long incubation with a streptavidin-phycoerythrin conjugate
(reporter). Standard, control, and experimental samples were then run in duplicate.
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Standard curve analysis was performed with Milliplex Analyst software. Curve fit was
produced with 5-parameter non-linear regression analysis and assay sample TNFa values
were interpolated from the standard curve. Results were normalized to total protein of the
original tissue homogenate, previously determined in BCA assay.

Statistical Analysis
Disease activity data was analyzed using independent t-tests within GraphPad
Prism analysis software. Analysis for successful development of colitis was performed
via comparison between water control and DSS colitis group (Group 1 versus Group 2).
DSS colitis groups receiving vehicle control injections were compared to DSS colitis
groups receiving the inhibitor (DPC-333) to determine the effects of the inhibitor (Group
2 versus Group 3).
Quantified TNFa levels were analyzed using independent t-tests within
GraphPad Prism analysis software. Analysis for successful development of colitis, and
thus induction of TNFa production, was performed with t-tests between water control
and DSS colitis groups receiving vehicle control injections (Group 1 versus Group 2).
Effect of the inhibitor on TNFa levels was determined through t-test between DSS colitis
groups receiving either vehicle control or DPC-333 injections (Group 2 versus Group 3).
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Tables
Table 1. Clinical Scoring Guide for Disease Activity Index determination. Disease
Activity Index (DAI) was calculated as the daily sum of clinical scoring parameters
including percent bodyweight change, stool consistency, and bleeding (Reproduced with
permission from Missouri State University, Maddox, 2015).
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Figures

Figure 21. Dose-dependent inhibition of sTNFα production in vivo. Dose dependent
sTNFα inhibition with DPC-333 was determined in male BALB/C mice challenged with
10 µg/mouse LPS IP injection. Determination of percent inhibition of sTNFα release was
achieved through comparison of plasma sTNFα concentrations following IP (solid line)
and oral (dotted line) doses of DPC-333 to vehicle control (Reproduced with permission
from The American Society for Pharmacology and Experimental Therapeutics: Drug
Metabolism and Disposition, Qian et al. 2007).
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Figure 22. Study Design. Mice were randomly assigned to one of three groups: a water
control (Group 1), a disease control (Group 2), and an experimental group (Group 3). For
7 days, mice consumed either untreated drinking water or 5% DSS in drinking water and
received twice daily injections of either the TACE inhibitor DPC-333 or its vehicle 25
mM citric acid saline. Every morning, food and water consumption as well as
bodyweight were recorded and clinical parameters were scored to create a disease activity
index. Following morning routine, mice were sacrificed and the distal 1 cm of colon was
removed.
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Figure 23. Luminex xMAP Technology and MagPix Multiplex System. The Luminex
MagPix system is a LED-based fluorescent detection system for protein quantification.
Antibody-conjugated magnetic beads are passed through a magnetic capture field and
excited with 635 nm LED. Resulting fluorescence intensity is used to quantify analyte
concentrations (Reprinted with permission from EMD, 2015).
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RESULTS

Clinical Scoring of 5% DSS Colitis
Effects of DSS Consumption on Colitis Development. The effects of 5% DSS
colitis were assessed via scoring of clinical parameters to create a disease activity index
(DAI). The results of this clinical assessment are summarized in Table 2. To evaluate the
successful induction of 5% DSS colitis, independent t-tests were performed to compare
groups 1 and 2 (Group 1: H2O + vehicle injection; Group 2: DSS + vehicle injection).
The effect of the TACE inhibitor during 5% DSS colitis was evaluated via independent ttest between groups 2 and 3 (Group 2: DSS + vehicle injection; Group 3: DSS + DPC-33
injection). Consumption of 5% DSS in drinking water for 7 days significantly increased
the DAI, indicating successful induction of colitis (p < 0.0001; Group 1 vs Group 2 on
day 7) (Figure 24). Diseased mice exhibited clinically relevant signs of colitis, such as
significant bodyweight loss, rectal bleeding, and diarrhea. TACE inhibition had no
significant effect on DAI and did not improve colitis (p = 0.74; Group 2 vs Group 3 on
day 7) (Figure 24). Diseased mice receiving the TACE inhibitor exhibited clinical signs
of colitis comparable to those that received only vehicle injections.
Bodyweight Loss in Response to DSS Consumption. The effects of DSS
consumption on bodyweight loss was evaluated via an independent t-test comparing
groups 1 and 2 (Group 1: H2O + vehicle injection; Group 2: DSS + vehicle injection).
Mice that consumed 5% DSS in drinking water exhibited significant bodyweight loss
compared to control mice (p = 0.0002; Group 1 vs Group 2 on day 7). An independent ttest between groups 2 and 3 (Group 2: DSS + vehicle injection; Group 3: DSS + DPC-
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333 injection) revealed that TACE inhibition had no effect on bodyweight loss (p = 0.45;
Group 2 vs Group 3 on day 7) (Figure 25); the final bodyweights of these mice were
comparable to diseased mice that received vehicle injections.
Effects of TACE Inhibition on Rectal Bleeding. An independent t-test
comparing groups 1 and 2 (Group 1: H2O + vehicle injection; Group 2: DSS + vehicle
injection) revealed that 5% DSS consumption induced significant gross bleeding at the
rectum as early as day 5 and continuing through day 7 (p < 0.0001; Group 1 vs Group 2
on day 7). To evaluate the effects of TACE inhibition on rectal bleeding, an independent
t-test between groups 2 and 3 (Group 2: DSS + vehicle injection; Group 3: DSS + DPC333 injection) was performed. No significant difference in rectal bleeding was observed
between these groups, indicating that TACE inhibition had no effect on the clinical
bleeding score (p = 1.00; Group 2 vs Group 3 on day 7) (Figure 26).
Alterations in Stool Consistency Following DSS Consumption. Occurrence of
loose stools and watery diarrhea in response to 5% DSS consumption were evaluated via
independent t-test between groups 1 and 2 (Group 1: H2O + vehicle injection; Group 2:
DSS + vehicle injection). Mice receiving DSS passed loose stools as early as day 5,
though a significant increase in loose stool scores was not seen until day 7 (p < 0.0001;
Group 1 vs Group 2). An independent t-test between groups 2 and 3 (Group 2: DSS +
vehicle injection; Group 3: DSS + DPC-333 injection) revealed that TACE inhibition had
no effect on stool consistency scores (p = 0.15; Group 2 vs Group 3) (Figure 27). In fact,
diseased mice receiving the TACE inhibitor exhibited signs of diarrhea comparable to
those that received only vehicle injection.
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Impact of DSS Consumption on Food and Water Consumption. Food and
water consumption were recorded daily for each group of mice in order to evaluate the
effects of DSS consumption and TACE inhibition on food and water intake. Quantitative
analysis of this data indicates that neither consumption of 5% DSS in drinking water nor
twice daily DPC-333 or vehicle injections had an effect on food and water intake (Figures
28 and 29). This suggests that mice consumed food and water regardless of the stressors
associated with experimental protocols.

Quantification of Colon TNFa Levels
Overview. Following 24-hour tissue culture, colon TNFa levels were measured
through multiplex immunoassay quantification of distal colon tissue homogenate and
normalized to total protein (pg/mg total protein acquired by BCA assay).
Effect of DSS Colitis on Colon TNFa Levels. The effect of 5% DSS
administration for 7 days on colon TNFa levels was evaluated via an independent t-test
between groups 1 and 2 (Group 1: H2O + vehicle injection; Group 2: DSS + vehicle
injection) (Figure 30). Although not statistically significant, consumption of 5% DSS for
7 days increased colon TNFa levels by 51.9% (p = 0.11; Group 1 vs Group 2) (Table 3),
suggesting that DSS-induced colitis up-regulates colon TNFa.
Colon TNFa Levels in Response to TACE Inhibition. The effect of TACE
inhibition on colon TNFa levels during 5% DSS colitis was evaluated through an
independent t-test between groups 2 and 3 (Group 2: DSS + vehicle injection; Group 3:
DSS + inhibitor injection) (Figure 30). TACE inhibition significantly reduced TNFa
levels by 56.2% (p = 0.017; Group 2 vs Group 3) (Table 3). These findings confirm that
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the TACE inhibitor DPC-333 is bioactive in the colon and that TACE inhibition
successfully reduces colon TNFa levels.
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Tables
Table 2. Analysis of clinical scoring in colitis development. p values were obtained from
an independent t-test comparing parameters on day 7 of 5% DSS. Group 1 (G1): H2O +
vehicle injection; Group 2 (G2): DSS + vehicle injection; Group 3 (G3): DSS + inhibitor
injection.

Table 3. TACE Inhibition during Colitis and Percent Difference in TNFα Concentration.
Results are independent t-test values of TNFα concentrations after 24-hour tissue culture.
Group 1 (G1): H2O + vehicle injection; Group 2 (G2): DSS + vehicle injection; Group 3
(G3): DSS + inhibitor injection.
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Figures

Figure 24. Average disease activity index (DAI) during development of 5% DSS-induced
colitis. DAI was quantified through scoring of clinical parameters as described in the text.
Values are group means ± SEM; * p<0.05 (DSS + vehicle versus respective H2O+vehicle
day). No significant difference between DSS + vehicle versus DSS + inhibitor.

Figure 25. Average bodyweight during development of colitis. Values are group means ±
SEM; * p<0.05 (DSS + vehicle versus respective H2O + vehicle day). No significant
difference between DSS + vehicle versus DSS + inhibitor.
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Figure 26. Bleeding scoring during development of colitis. Values are group means ±
SEM; * p<0.05 (DSS + vehicle versus respective H2O+vehicle day). No significant
difference between DSS + vehicle versus DSS + inhibitor.

Figure 27. Stool consistency scoring during development of colitis. Values are group
means ± SEM; * p<0.05 (DSS + vehicle versus respective H2O+vehicle day). No
significant difference between DSS + vehicle versus DSS + inhibitor.
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Figure 28. Food consumption during development of colitis. Values are group means ±
SEM. No significant difference between groups.

Figure 29. Water consumption during development of colitis. Values are group means ±
SEM. No significant difference between groups.
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Figure 30. Effect of DSS colitis and TACE inhibition on colon TNFa. Tissue TNFa
concentrations were quantified after 7 days of 5% DSS. Groups received twice daily IP
injections of either 10 mg/kg DPC-333 or an equivalent volume of vehicle (25mM citric
acid saline). Values are group means ± SEM; *p<0.05 (DSS + vehicle versus DSS +
inhibitor).
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DISCUSSION

Novel Impact of Data Collected and Rejection of Hypothesis
BALB/C Mouse Model as Primary Non-Responders to Anti-TNFa Therapy.
Current literature and research on the DSS model of clinical colitis demonstrate that the
disease model and findings vary between mouse strain, thus establishing difference in
susceptibility to DSS-induced colitis are due to genetic background. A 2005 study by
Melgar et al. observed the differences in response to DSS between C57/BL6 and
BALB/C mice (Table 4). While BALB/C mice recover after termination of DSS
administration for 7 days, C57/BL6 progress to chronic disease. These two models of
colitis also differ in the concentration of DSS tolerated and the inflammatory cytokines
produced. Identification and quantification of inflammatory cytokines revealed that the
acute colitis in BALB/C may be macrophage-driven, while the progression to chronic
disease in C57/BL6 mice may be T-cell-driven.
Additionally, studies of TACE inhibition in DSS colitis models vary widely in
methods (DasGupta et al., 2008). One study provided evidence for TACE inhibition
improving disease phenotype in C57/BL6 mice by giving twice daily IP injections of the
TACE inhibitor DPC-333 during 7 days of DSS administration (Sharma et al., 2014).
Concurrent with the methods of Sharma et al., Maddox demonstrated that administration
of DPC-333 does not improve the disease state in a BALB/C model of DSS colitis. This
study improved upon the methods of Maddox by conducted a single-blind randomized
study to prevent bias in phenotyping of clinical symptoms. Additionally, a 24-hour tissue
incubation step was included to allow for continued cytokine production and resulted in
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more significant readings of colon TNFa Furthermore, DPC-333 was observed to be
bioactive in the target tissue, knocking down colon TNFa levels to concentrations
comparable to those of healthy animals. These results suggest that TNFa is not involved
in the development of DSS colitis in the BALB/C model and that an alternative pathway
may exist.
Further research is necessary to determine the mechanism behind primary nonresponse to anti-TNFa treatments and characterize an alternative pathway in colitis
development. In light of the failure of TACE inhibition to resolve the disease phenotype
in BALB/C mice, it is possible that the BALB/C colitis model could serve as a preclinical model of study for IBD patients who do not respond to anti-TNFa treatments.

Future Directions and Preliminary Data in C57/BL6 Mice
TNFa Involvement in BALB/C Colitis Models. It has long been established that
TNFa is a key player in the development and progression of IBD. However, current
research suggests that TNFa may not be the driving force in some forms of IBD. Further
research is necessary to determine an alternative driving force for inflammation and an
animal model that does not respond to anti-TNFa therapies could provide insight in these
cases. We have confirmed that BALB/C mice fail to respond to TACE inhibition during
DSS colitis, thus, we find it pertinent to provide further evidence for the lack of
involvement of TNFa in BALB/C colitis models by conducting an identical study in
C57/BL6 mice. Although our methods were adopted from the study of TACE inhibition
in the C57/BL6 model of DSS colitis conducted by Sharma et al., we are currently
recreating this study to generate data with which we can compare the response of these
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two mouse models to TACE inhibition. Although preliminary data shows no statistically
significant difference in disease activity between the three groups (Group 1: H2O +
vehicle, n=4; Group 2: DSS + vehicle, n=4; Group 3: DSS + inhibitor, n=4), there
appears to be a trend for improvement of disease activity with TACE inhibition (p =
0.0758) (Figure 31).
If a difference in response to TACE inhibition is observed between C57/BL6 and
BALB/C mice, it would be necessary to investigate BALB/C response to TACE
inhibition in colitis induced by other methods as well as response to other forms of antiTNFa therapy. Lack of response to all forms of anti-TNFa treatments in multiple colitis
models would provide sufficient evidence to suggest that BALB/C mice are a pre-clinical
model of study for a form of IBD in which TNFa is not involved.
Alternative Driving Forces in IBD. Evidence suggests that forms of IBD exist in
which TNFa is not the driving force for inflammation, thus, alternative pathways of
colitis development need to be investigated. Determination of an alternative driving force
might prove a difficult feat due to the variety of factors involved in IBD development,
such as genetics, signaling pathways, diet, and microbiota composition. Because
BALB/C and C57/BL6 mice vary in their response to DSS-induced colitis, study of the
differing pro-inflammatory cytokines between the two models might illuminate an
alternative cytokine as the driving force for inflammation in BALB/C mice. Additionally,
comparison of the genetic backgrounds of the two mouse strains might shed light on
genetic factors behind non-TNFa-mediated colitis.
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Impact of Results on Current Directions in IBD Research- Alternative Therapeutics
for Non-Responders
Overview. The failure of current pharmaceuticals to completely ameliorate colitis
has led current IBD research to broaden its horizons. Traditionally, the focus has been on
anti-inflammatory agents that modulate the immune system, with the intestinal immune
response as the key focus of developing therapies (Bernstein, 2015). Research has now
shifted its focus to developing new therapeutics, investigating the role of the gut
microbiota in IBD development, and improving clinical assessment protocols and clinical
goals to optimize personalized patient treatments (Löwenberg & Haens, 2015; Marchesi
et al., 2015; Levesque et al., 2015).
Novel Therapeutics for IBD. Recently, various novel drugs have been evaluated
in clinical trials, showing promising outcomes in IBD patients. These drugs include small
molecules interfering with intracellular signaling pathways and therapeutic antibodies
directed against extracellular targets.
Golimumab, a novel anti-TNFa monoclonal antibody, has recently been approved
by the US Food and Drug Administration (FDA) and the European Medicines Agency
(EMA) for UC patients with moderate to severe IBD (Löwenberg & Haens, 2015).
Induction treatment with golimumab in UC patients naïve to biologic treatment
significantly increased clinical response, remission, and mucosal healing rates at week 6
compared to a placebo (Sandborn et al., 2014).
Several agents interfering with leukocyte trafficking have been developed to
selectively target cell adhesion molecules and interfere with T-cell trafficking. The
recently developed therapies vedolizumab, etrolizumab, and PF-00547659 are more gut
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selective than previous leukocyte trafficking drugs, and have so far not led to progressive
multifocal leukoencephalopathy (PML) (Löwenberg & Haens, 2015).
Orally active small molecules represent novel therapeutics that interfere with
intracellular signaling and have lower production costs than therapeutic antibodies. So
far, Janus kinase (JAK) inhibitors are the most developed small molecules, one of which
has already been approved and marketed for treatment of rheumatoid arthritis. JAKs play
a major role in regulation of cell proliferation, differentiation, and immune cell function.
JAK-dependent signaling pathways are known to be involved in chronic inflammatory
pathologies, such as rheumatoid arthritis and IBD. Thus, JAK inhibition is a novel
approach to IBD treatment as an anti-inflammatory therapy (Löwenberg & Haens, 2015).
Gut Microbiota Modulation as an IBD Therapy. Early studies of intestinal
bacteria in IBD pathogenesis focused on identifying a specific cell population that could
potentially initiate colitis. Recently, the realization that the gut microbiota as a whole is
altered in IBD has shifted the focus to microbiota modulation as a therapy. Changes in
gut microbiota composition, such as a reduction in Firmicutes coincident with an increase
in Bacteroidetes, have been reported in patients with IBD. Furthermore, certain changes
have been clearly linked to either CD or UC.
Several clinical trials have investigated modulation of the microbiota in IBD
through antibiotics, probiotics, prebiotics, enteral nutrition, and fecal transfer.
Randomized controlled trials of antibiotic combinations in CD and UC have
demonstrated beneficial effects and antibiotics are a popular treatment for perineal
fistulizing CD. While proof of safety and efficacy are lacking for the use of probiotics,
there are promising results for E. coli Nissle 1917 as a maintenance therapy for UC.
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Prebiotics are food substances that are not digested in the small intestine and promote
selective growth of beneficial bacteria in the colon. To date, no proof of benefit from
prebiotic treatment exists for IBD patients, although their use is still being investigated.
Modulation of enteric nutrition through specialized dietary formulations has
demonstrated effectiveness in treatment of pediatric CD. Thus, this approach has been
widely adopted by pediatric gastroenterologists. Finally, fecal transfer has been
considered in the treatment of IBD; however, in IBD, the microbiota is altered very
permanently and preliminary data on randomized controlled trial of fecal transplantation
by enema in UC was negative (Bernstein, 2015). Thus, investigation of definitive
microbiota abnormalities in IBD is ongoing with the hope that better understanding will
lead to novel therapeutic approaches.
Improvement of Clinical Assessment and Practices. Therapeutic advances and
better understanding of IBD have led to a shift in the assessment of disease activity, as
remission targets are more achievable (Walsh et al., 2016). IBD management goals have
been based on composite indices which incorporate symptoms, signs, laboratory test
results, and endoscopic assessments. Because these indices are complex and not intuitive
to clinicians, or individual patient phenotypes, there is a disconnect between clinical trials
and practice. Consideration of patient-reported outcomes, in addition to use of these
composite indices, could provide a clinically meaningful and scientifically valid
assessment of disease activity (Levesque et al., 2015). Thus, focus has shifted to finetuning disease activity assessment protocols and combination therapies with the hopes of
personalizing IBD management plans to individual patients.
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One aspect of this new goal is to predict patient response to anti-TNFa therapies
so as to design a practical management plan to optimize response prior to treatment. One
recent study formulated clinical algorithms that employ therapeutic drug monitoring to
determine the underlying cause of primary non-response and secondary loss of response
(Figure 32). Ultimately, these algorithms should allow clinicians to identify which
patients are most likely to respond to anti-TNFa therapies and optimize drug therapy for
those who are losing response (Ding et al., 2015).
Additionally, new serological markers are being utilized in the prediction of IBD
patient outcomes. So far, only anti-neutrophilic cytoplasmic antibodies (ANCA) and antiSaccharomyces cerevisiae antibodies (ASCA) have demonstrated diagnostic ability and
their simultaneous use allows for distinction between CD and UC. More recently,
antibodies such as anti-glycoprotein 2 (anti-GP2) and anti-granulocyte macrophage
colony-stimulating factor (anti-GM-CSF) have been identified in IBD patients. GP2 is
thought to play an immunomodulatory role in the intestinal immune system, while GMCSF promotes myeloid cell maturation and is necessary for homeostatic responses to
tissue damage. Both proteins have been demonstrated to be neutralized in the serum of
IBD patients, while their antibodies are up-regulated (Bonneau et al., 2014). Thus,
identification and use of serological markers could improve IBD diagnosis and optimize
personalization of management plans.

Limitations of this Study
Type of Murine Colitis Model. The DSS model represents only one type of
colitis mouse model and presents potential limitations. Because the mechanism behind
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DSS-induced colitis is poorly understood, no potential systemic effects have been
identified (Dieleman et al., 1994); thus, we cannot control for any underlying issues that
might skew our study. Furthermore, chemically-induced colitis models receiving a drug
or vehicle treatment could be experiencing drug interactions that researchers are unaware
of. Ideally, a model of colitis would be generated in which BALB/C mice spontaneously
develop intestinal inflammation as a result of genetic and environmental factors.
However, the only known murine models that develop spontaneous colitis are the
SAMP1/Yit or C3H/H3JBir models which were referenced in the introduction (Hoffman
et al., 2002). Induction of spontaneous colitis in BALB/C mice would require mutations
in IBD-associated genes similar to those observed in human IBD, the exact details of
which would take time and extensive resources to determine.
Method of TACE Inhibition. TACE inhibition is a novel approach to TNFa
blockade in inflammatory pathologies. Reducing TNFa upstream of membrane shedding
prevents soluble TNFa production, thus effectively down-regulating the amount of
TNFa that can activate TNFRs (Ruuls et al., 2001). However, TACE inhibition did not
progress past phase II clinical trials due to liver toxicity concerns (Reviewed by
DasGupta et al., 2008). It remains to be seen whether liver toxicity occurs in response to
TACE inhibitor use in mice and if the effects of liver toxicity could affect our colitis
model.
As mentioned earlier, we do not know of any drug interactions between DSS and
DPC-333; if an interaction exists, this could also affect our study. Additionally, DPC-333
was solubilized in 25 mM citric acid (CA) saline; although our water control group
accounted for any adverse effects to CA saline, we do not know what those effects might
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be. Furthermore, administering DPC-333 through twice daily IP injection caused stress to
the mice, as well as abdominal bruising. For this study, an ideal TACE inhibitor would be
bioactive only in the target tissue (i.e. the colon) following oral administration, thus
eliminating the pain and stress associated with needle injections.
Confirmation of Role for TNFa in Colitis Development. Blocking TNFa
signaling by TACE inhibition is effective in preventing soluble TNFa production, thus
reducing the amount of TNFa that could activate membrane-bound TNFRs on other
inflammatory cells (Ruuls et al., 2001). However, TACE inhibition does not completely
prevent TNFa signaling; it is possible for membrane-bound TNFa to interact with
TNFRs on neighboring inflammatory cells that come into contact with the plasma
membrane (Figure 33) (Campbell et al., 2003).
Generation of a TNFa knockout (KO) or a TNFR KO mouse, in which TNFa
signaling is completely ablated, would allow for conclusive study of the role of TNFa in
the BALB/C colitis model. Convincing evidence that TNFa is not involved in the
development of colitis in BALB/C mice would be provided if TNFa is effectively
knocked out in these mice yet colitis development still occurs. Ideally, a mouse would
have to be generated in which TNFa knockout only occurs in the colonic epithelium and
mucosal tissues. One major limitation to this approach is that infiltrating inflammatory
cells would still produce TNFa; thus, ablation of TNFa signaling in leukocytes would be
necessary. However, this systemic ablation of TNFa signaling would induce systemic
side effects, such as immunosuppression and prolonged recovery from injury that could
skew the study (Bruce et al., 1996). Developing a perfect model in which to study the
role of TNFa in the development of colitis in BALB/C mice may be impossible. Further
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study of current models is necessary to understand all of the interactions involved and
ensure that future colitis studies can control for unwanted systemic and local side effects.

Overall Conclusions
Management and treatment of IBD proves difficult due to the complexity of the
mechanisms involved in pathologic inflammation. In fact, it is possible that there are
factors yet to be discovered. Currently, anti-TNFa therapies are the standard in IBD
treatment as it has been established that TNFa drives inflammation in many
inflammatory diseases; however, one-third of IBD patients do not respond to anti-TNFa
therapies and many primary responders exhibit secondary loss of response (Papadakis et
al., 2005). This study demonstrates the failure of BALB/C mice to respond to anti-TNFa
therapy via TACE inhibition in a DSS-induced model of colitis, suggesting that forms of
colitis exist in which TNFa is not the driving force for inflammation. This finding
highlights the need for new approaches to IBD management in unique patient cohorts and
supports the endeavors of current research to formulate personalized management plans
for IBD patients.
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Tables
Table 4. Two colitis models emphasize role for genetics in colitis development. During
DSS administration, BALB/C mice develop an acute colitis characterized by the upregulation of cytokines involved in a macrophage-mediated inflammatory response.
Following DSS termination, BALB/C mice enter a recovery phase in which they are
symptom-free within 2 weeks and completely recovered by day 28. In contrast, C57/BL6
mice progress to a severe chronic colitis following DSS termination characterized by the
up-regulation of cytokines involved in T cell-mediated inflammation. This study
concluded that genetic background plays a role in the development of colitis (Adapted
from the American Journal of Physiology, Acute colitis induced by dextran sulfate
sodium progresses to chronicity in C57/BL6 mice but not in BALB/C mice: correlation
between symptoms and inflammation, Melgar et al., 2005, with permission from the
American Physiological Society).
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Figures

Figure 31. Average disease activity index (DAI) during development of colitis in
C57/BL6 mice. DAI was quantified through scoring of clinical parameters, such as
percent bodyweight loss, rectal bleeding, and stool consistency. Values are groups means
± SEM. DSS consumption significantly increased DAI (*p < 0.05; DSS + veh versus
respective H2O + veh day). Although not statistically significant, there appears to be a
trend for improvement in DAI following TACE inhibition (p = 0.0758).
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Figure 32. Proposed algorithm for managing primary nonresponse to anti-TNF therapy in
Crohn’s disease. These algorithms employ therapeutic drug monitoring to determine the
underlying cause of nonresponse or loss of response to anti-TNF therapies. This strategy
should allow clinicians to identify patients that are most likely to respond to anti-TNF
treatments and optimize therapies for those who are losing response (Reproduced from
Alimentary Pharmacology & Therapeutics, Systematic review: predicting and optimising
response to anti-TNF therapy in Crohn’s disease - algorithm for practical management,
Ding et al., 2015, with permission from John Wiley and Sons).
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Figure 33. Membrane-bound TNF-alpha can interact with TNF receptors on neighboring
cells. TNF-alpha signaling can occur through either soluble or membrane-bound TNFalpha binding to membrane-bound receptors on other inflammatory cells (Reprinted by
permission from Macmillan Publishers Ltd: Immunology and Cell Biology, Campbell et
al., copyright 2003).
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